"Ritonavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.
| Descriptor ID |
D019438
|
| MeSH Number(s) |
D02.886.675.653 D03.383.129.708.653
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ritonavir".
Below are MeSH descriptors whose meaning is more specific than "Ritonavir".
This graph shows the total number of publications written about "Ritonavir" by people in this website by year, and whether "Ritonavir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 3 | 0 | 3 |
| 2006 | 1 | 1 | 2 |
| 2008 | 1 | 1 | 2 |
| 2010 | 2 | 4 | 6 |
| 2011 | 3 | 3 | 6 |
| 2012 | 3 | 3 | 6 |
| 2013 | 2 | 2 | 4 |
| 2014 | 2 | 2 | 4 |
| 2015 | 5 | 3 | 8 |
| 2016 | 3 | 2 | 5 |
| 2017 | 2 | 2 | 4 |
| 2018 | 3 | 2 | 5 |
| 2019 | 0 | 5 | 5 |
| 2020 | 3 | 3 | 6 |
| 2021 | 1 | 4 | 5 |
| 2022 | 0 | 3 | 3 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ritonavir" by people in Profiles.
-
Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age. Pediatr Infect Dis J. 2024 Apr 01; 43(4):355-360.
-
Drug-drug interaction with oral antivirals for the early treatment of COVID-19. Int J Infect Dis. 2023 02; 127:171-172.
-
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. J Int AIDS Soc. 2022 06; 25(6):e25905.
-
Quality of life and associated factors among people receiving second-line anti-retroviral therapy in Johannesburg, South Africa. BMC Infect Dis. 2022 May 12; 22(1):456.
-
Persistently lower bone mass and bone turnover among South African children living with well controlled HIV. AIDS. 2021 11 01; 35(13):2137-2147.
-
Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. Clin Infect Dis. 2021 08 16; 73(4):706-715.
-
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age. AIDS. 2021 07 15; 35(9):1413-1421.
-
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Clin Pharmacol Ther. 2021 10; 110(4):1057-1065.
-
Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life. Sci Rep. 2021 02 04; 11(1):3173.
-
The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells. Biomed Pharmacother. 2020 Dec; 132:110829.